7W3.F ACOTEC SCIEN.H. DL-00001
- Market cap
- EUR 172M
- P/E
- -
- P/B
- 0.93x
- ROE
- 8.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 7W3.F undervalued?
Graham numberThe Graham number of ACOTEC SCIEN.H. DL-00001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ACOTEC SCIEN.H. DL-00001 fundamental analysis
No fundamental analysis for ACOTEC SCIEN.H. DL-00001 yet.
ACOTEC SCIEN.H. DL-00001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ACOTEC SCIEN.H. DL-00001
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coat…
Full company profileACOTEC SCIEN.H. DL-00001 financial statements
ACOTEC SCIEN.H. DL-00001 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 304M | 396M | 474M | 534M | 645M |
| Gross Profit | 266M | 336M | 377M | 403M | 476M |
| Operating Income | -26.7M | -65.0K | 21.6M | 36.9M | 105M |
| EBITDA | - | 91.2M | 70.5M | 112M | 185M |
| Net Income | -79.1M | 70.1M | 14.5M | 52.3M | 119M |
| EPS | -0.25 | 0.22 | 0.05 | 0.17 | 0.38 |
| Balance Sheet | |||||
| Total Assets | 1.31B | 1.41B | 1.61B | 1.66B | 1.87B |
| Total Liabilities | 100M | 134M | 315M | 313M | 392M |
| Shareholders' Equity | 1.21B | 1.28B | 1.30B | 1.35B | 1.48B |
| Cash & Short-term Investments | 1.14B | 986M | 638M | 751M | 400M |
| Cash Flow | |||||
| Operating Cash Flow | -10.5M | -68.8M | -12.9M | 103M | 150M |
| Capital Expenditure | 21.2M | 46.7M | 79.7M | 97.5M | 81.2M |
| Free Cash Flow | -31.7M | -115M | -92.5M | 5.31M | 69.1M |
| Ratios | |||||
| ROE | -6.6% | 5.5% | 1.1% | 3.9% | 8.1% |
| ROA | -6.0% | 5.0% | 0.9% | 3.1% | 6.4% |
| Net Profit Margin | -26.0% | 17.7% | 3.1% | 9.8% | 18.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ACOTEC SCIEN.H. DL-00001 dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | CNY 323M | 1.03 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns ACOTEC SCIEN.H. DL-00001
- Insiders 83.59%
- Institutions 0.17%
- Public & others 16.24%
- Shares outstanding 313M
- Free float 50.8M
ACOTEC SCIEN.H. DL-00001 company profile
- Company name
- ACOTEC SCIEN.H. DL-00001
- Ticker
- 7W3.F
- ISIN
- KYG0096M1096
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 955
- Fiscal year end
- December
- Address
- Building No. 1, Beijing, China
- Phone
- 86 10 6787 2107
- Website
- acotec.cn
About ACOTEC SCIEN.H. DL-00001
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee arteries for the treatment of chronic limb-threatening ischemia with a vascular interventional approach. It also offers devices for vascular surgery, including AcoArt Iris & Jasmin; AcoArt Lily & Rosmarin; peripheral aspiration system; radiofrequency ablation system; peripheral support catheter; The PTA balloon; 2nd gen peripheral aspiration system; introducer sheath set; and the delivery catheter for aspiration catheter. In addition, it offers cardiology devices, including semi-compliant PTCA balloon; coronary CTO recanalization balloon; coronary CTO antegrade micro-catheter; coronary high-pressure balloon; cardiac valve balloon dilation catheter; AcoArt Camellia; and coronary micro-catheter. Further, the company provides nephrology devices, such as paclitaxel coated high-pressure balloon and AV scoring balloon; and neurology devices comprising intracranial PTA balloons and vertebral artery paclitaxel-coated balloon dilatation catheter, as well as trades in procedural medical devices. The company was founded in 2011 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of Boston Scientific Group plc.
ACOTEC SCIEN.H. DL-00001 management
4- Ms. Jing LiExecutive Chairperson of the Board & CEO · born 1973
- Dr. Ulrich Reinhold SpeckChief Technology Officer · born 1942
- Mr. Chen LiJoint Company Secretary · born 1991
- Ms. Ching Yi LiJoint Company Secretary